Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer
The purpose of this study is to determine whether exemestane plus everolimus are effective in the treatment of patients who have achieved disease stabilization after induction chemotherapy for hormone-receptor positive metastatic breast cancer.
Hormone Receptor Positive Malignant Neoplasm of Breast
DRUG: Exemestane|DRUG: Everolimus
Progression Free Survival, defined as from date of treatment initiation with everolimus plus exemestane to the date of progression or death if no documented disease progression, Every 8 weeks in the first 24 weeks of treatment and every 12 weeks thereafter, up to 8 months (estimated)
Response rate, Every 8 weeks, up to 8 months (estimated)|Clinical benefit rate, Every 8 weeks, up to 8 months (estimated)|Overall survival, date of treatment initiation with everolimus plus exemestane until the date of death, censored at the last date known alive, whichever came first, assessed up to 32 months|Incidence of Adverse Events (AEs)/Serious Adverse Events (SAEs), Continuous during the study, up to 28 days after the last treatment
Postmenopausal women with HR-positive, HER2-negative metastatic breast cancer achieving clinical benefit after the induction chemotherapy for visceral disease with sign(s) and/or symptom(s) will be recruited to receive study the maintenance treatment of everolimus plus exemestane.